Research programme: kinase inhibitor drug conjugates - Tarveda Therapeutics
Latest Information Update: 21 Aug 2023
At a glance
- Originator Synta Pharmaceuticals
- Developer Madrigal Pharmaceuticals
- Class Antineoplastics; Drug conjugates; Small molecules
- Mechanism of Action 1 Phosphatidylinositol 3 kinase inhibitors
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity Yes
Highest Development Phases
- Preclinical Solid tumours
Most Recent Events
- 21 Aug 2023 Preclinical development is ongoing in USA (SciClone Pharmaceuticals, Pipeline August 2023)
- 28 Mar 2022 No recent reports of development identified for preclinical development in Solid-tumours in USA
- 16 Sep 2021 Kinase inhibitor drug conjugates licensed to SciClone Pharmaceuticals in China, Macau, Hong Kong, Taiwan